Cas:50984-88-8 p-xylenolphthalein manufacturer & supplier

We serve Chemical Name:p-xylenolphthalein CAS:50984-88-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

p-xylenolphthalein

Chemical Name:p-xylenolphthalein
CAS.NO:50984-88-8
Synonyms:3,3-Bis(4-hydroxy-2,5-dimethylphenyl)isobenzofuran-1(3H)-one;EINECS 256-893-4;2′,5′,2”,5”-Tetramethylphenolphthalein;p-Xylenolphthalein;2,2′,5,5′-Tetramethylphenolphthalein;MFCD00042785
Molecular Formula:C24H22O4
Molecular Weight:374.42900
HS Code:2932209090

Physical and Chemical Properties:
Melting point:276°C
Boiling point:569.6ºC at 760mmHg
Density:1.27g/cm3
Index of Refraction:1.649
PSA:66.76000
Exact Mass:374.15200
LogP:4.79370

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 3,3-Bis(4-hydroxy-2,5-dimethylphenyl)isobenzofuran-1(3H)-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00042785 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,p-Xylenolphthalein Use and application,p-Xylenolphthalein technical grade,usp/ep/jp grade.


Related News: While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added. p-xylenolphthalein manufacturer The chemical compound which is in the process of becoming an API from a raw material is called an intermediate. p-xylenolphthalein supplier Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition. p-xylenolphthalein vendor Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition. p-xylenolphthalein factory While they are early data, “it’s also very reassuring that those patients who have progressed can be rather easily reinduced into remission,” Tendler said. J&J and AbbVie are now taking the same approach for the GLOW study, he added.